+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Non-infectious Macular Edema Treatment - Global Market Trajectory & Analytics

  • ID: 5309816
  • Report
  • April 2021
  • Region: Global
  • 139 pages
  • Global Industry Analysts, Inc
Global Non-infectious Macular Edema Treatment Market to Reach $14.9 Billion by 2027

Amid the COVID-19 crisis, the global market for Non-infectious Macular Edema Treatment estimated at US$10.2 Billion in the year 2020, is projected to reach a revised size of US$14.9 Billion by 2027, growing at a CAGR of 5.6% over the analysis period 2020-2027. Anti-VEGF, one of the segments analyzed in the report, is projected to record a 5.4% CAGR and reach US$6.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Corticosteroids segment is readjusted to a revised 5.8% CAGR for the next 7-year period.



The U.S. Market is Estimated at $3 Billion, While China is Forecast to Grow at 5.2% CAGR

The Non-infectious Macular Edema Treatment market in the U.S. is estimated at US$3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2027 trailing a CAGR of 5.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.3% and 4.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Immunosuppressant Segment to Record 6.4% CAGR

In the global Immunosuppressant segment, USA, Canada, Japan, China and Europe will drive the 6.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.4 Billion in the year 2020 will reach a projected size of US$2.2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.7 Billion by the year 2027.

Select Competitors (Total 46 Featured):
  • AbbVie, Inc.
  • Alimera Sciences, Inc.
  • Allergan PLC
  • Amgen, Inc.
  • Bausch Health Companies, Inc.
  • Bayer AG
  • Clearside Biomedical, Inc.
  • F. Hoffmann-La Roche AG
  • Novartis International AG
  • Pfizer, Inc.
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Current & Future Analysis for Non-infectious Macular Edema Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World Historic Review for Non-infectious Macular Edema Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 3: World 15-Year Perspective for Non-infectious Macular Edema Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
  • Table 4: World Current & Future Analysis for Anti-VEGF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 5: World Historic Review for Anti-VEGF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 6: World 15-Year Perspective for Anti-VEGF by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 7: World Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 8: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 9: World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 10: World Current & Future Analysis for Immunosuppressant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 11: World Historic Review for Immunosuppressant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 12: World 15-Year Perspective for Immunosuppressant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 13: World Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 14: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 15: World 15-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
  • Table 16: World Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 17: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 18: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
  • UNITED STATES
  • Table 19: USA Current & Future Analysis for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 20: USA Historic Review for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 21: USA 15-Year Perspective for Non-infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types for the Years 2012, 2020 & 2027
  • CANADA
  • Table 22: Canada Current & Future Analysis for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 23: Canada Historic Review for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 24: Canada 15-Year Perspective for Non-infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types for the Years 2012, 2020 & 2027
  • JAPAN
  • Table 25: Japan Current & Future Analysis for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 26: Japan Historic Review for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 27: Japan 15-Year Perspective for Non-infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types for the Years 2012, 2020 & 2027
  • CHINA
  • Table 28: China Current & Future Analysis for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 29: China Historic Review for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 30: China 15-Year Perspective for Non-infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types for the Years 2012, 2020 & 2027
  • EUROPE
  • Table 31: Europe Current & Future Analysis for Non-infectious Macular Edema Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 32: Europe Historic Review for Non-infectious Macular Edema Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 33: Europe 15-Year Perspective for Non-infectious Macular Edema Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
  • Table 34: Europe Current & Future Analysis for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 35: Europe Historic Review for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 36: Europe 15-Year Perspective for Non-infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types for the Years 2012, 2020 & 2027
  • FRANCE
  • Table 37: France Current & Future Analysis for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 38: France Historic Review for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 39: France 15-Year Perspective for Non-infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types for the Years 2012, 2020 & 2027
  • GERMANY
  • Table 40: Germany Current & Future Analysis for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 41: Germany Historic Review for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 42: Germany 15-Year Perspective for Non-infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types for the Years 2012, 2020 & 2027
  • ITALY
  • Table 43: Italy Current & Future Analysis for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 44: Italy Historic Review for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 45: Italy 15-Year Perspective for Non-infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
  • Table 46: UK Current & Future Analysis for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 47: UK Historic Review for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 48: UK 15-Year Perspective for Non-infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types for the Years 2012, 2020 & 2027
  • REST OF EUROPE
  • Table 49: Rest of Europe Current & Future Analysis for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 50: Rest of Europe Historic Review for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 51: Rest of Europe 15-Year Perspective for Non-infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
  • Table 52: Asia-Pacific Current & Future Analysis for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 53: Asia-Pacific Historic Review for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 54: Asia-Pacific 15-Year Perspective for Non-infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types for the Years 2012, 2020 & 2027
  • REST OF WORLD
  • Table 55: Rest of World Current & Future Analysis for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 56: Rest of World Historic Review for Non-infectious Macular Edema Treatment by Drug Type - Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
  • Table 57: Rest of World 15-Year Perspective for Non-infectious Macular Edema Treatment by Drug Type - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroids, Immunosuppressant, Biologics and Other Drug Types for the Years 2012, 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 46
Note: Product cover images may vary from those shown
Adroll
adroll